Original Research Article

Clinical Pharmacokinetics

, Volume 49, Issue 7, pp 449-454

First online:

Steady-State Pharmacokinetics and Tolerability of Trans-Resveratrol 2000mg Twice Daily with Food, Quercetin and Alcohol (Ethanol) in Healthy Human Subjects

  • Charles la PorteAffiliated withThe Ottawa Hospital Research InstituteUniversity of Ottawa Email author 
  • , Nha VoducAffiliated withUniversity of Ottawa
  • , Guijun ZhangAffiliated withThe Ottawa Hospital Research Institute
  • , Isabelle SeguinAffiliated withThe Ottawa Hospital Research Institute
  • , Danielle TardiffAffiliated withThe Ottawa Hospital Research Institute
  • , Neera SinghalAffiliated withThe Ottawa Hospital Research InstituteUniversity of Ottawa
  • , D. William CameronAffiliated withThe Ottawa Hospital Research InstituteUniversity of Ottawa

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Background and Objective

Trans-resveratrol is a polyphenol, which is found in red wine and has cancer chemo-preventive properties and disease-preventive properties. The pharmacokinetics of trans-resveratrol have been investigated in single-dose studies and in studies with relatively low dosages. The present study aimed to investigate the steady-state pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol).


This was a two-period, open-label, single-arm, within-subject control study in eight healthy subjects. The steady-state 12-hour pharmacokinetics of trans-resveratrol 2000 mg twice daily were studied with a standard breakfast, a high-fat breakfast, quercetin 500 mg twice daily and 5% alcohol 100 mL. Trans-resveratrol plasma concentrations were determined using liquid chromatography with tandem mass spectrometry.


The mean (SD) area under the plasma concentration-time curve from 0 to 12 hours (AUC12) and maximum plasma concentration (Cmax) of trans-resveratrol were 3558 (2195) ng •h/mL and 1274 (790) ng/mL, respectively, after the standard breakfast. The high-fat breakfast significantly decreased the AUC12 and Cmax by 45% and 46%, respectively, when compared with the standard breakfast. Quercetin 500 mg twice daily or 5% alcohol 100mL did not influence trans-resveratrol pharmacokinetics. Diarrhoea was reported in six of the eight subjects. Significant but not clinically relevant changes from baseline were observed in serum potassium and total bilirubin levels.


Trans-resveratrol 2000 mg twice daily resulted in adequate exposure and was well tolerated by healthy subjects, although diarrhoea was frequently observed. In order to maximize trans-resveratrol exposure, it should be taken with a standard breakfast and not with a high-fat meal. Furthermore, combined intake with quercetin or alcohol did not influence trans-resveratrol exposure.